Logo image of DBV.PA

DBV TECHNOLOGIES SA (DBV.PA) Stock Price, Quote, News and Overview

EPA:DBV - Euronext Paris - Matif - FR0010417345 - Common Stock - Currency: EUR

0.812  +0.03 (+3.44%)

DBV.PA Quote, Performance and Key Statistics

DBV TECHNOLOGIES SA

EPA:DBV (3/7/2025, 7:00:00 PM)

0.812

+0.03 (+3.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.55
52 Week Low0.51
Market Cap16.66M
Shares20.52M
Float17.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-28 2025-07-28
IPO03-29 2012-03-29


DBV.PA short term performance overview.The bars show the price performance of DBV.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

DBV.PA long term performance overview.The bars show the price performance of DBV.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of DBV.PA is 0.812 EUR. In the past month the price increased by 1%. In the past year, price decreased by -42.74%.

DBV TECHNOLOGIES SA / DBV Daily stock chart

DBV.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About DBV.PA

Company Profile

DBV logo image DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 106 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

Company Info

DBV TECHNOLOGIES SA

Batiment IRO, 107 Av. de la Republique

Chatillon AUVERGNE-RHONE-ALPES FR

Employees: 106

Company Website: https://www.dbv-technologies.com/

Investor Relations: https://dbv-technologies.com/investor-overview/

Phone: 33155427878

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the stock price of DBV TECHNOLOGIES SA today?

The current stock price of DBV.PA is 0.812 EUR. The price increased by 3.44% in the last trading session.


What is the ticker symbol for DBV TECHNOLOGIES SA stock?

The exchange symbol of DBV TECHNOLOGIES SA is DBV and it is listed on the Euronext Paris - Matif exchange.


On which exchange is DBV.PA stock listed?

DBV.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for DBV TECHNOLOGIES SA stock?

7 analysts have analysed DBV.PA and the average price target is 6.38 EUR. This implies a price increase of 685.1% is expected in the next year compared to the current price of 0.812. Check the DBV TECHNOLOGIES SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is DBV TECHNOLOGIES SA worth?

DBV TECHNOLOGIES SA (DBV.PA) has a market capitalization of 16.66M EUR. This makes DBV.PA a Nano Cap stock.


How many employees does DBV TECHNOLOGIES SA have?

DBV TECHNOLOGIES SA (DBV.PA) currently has 106 employees.


What are the support and resistance levels for DBV TECHNOLOGIES SA (DBV.PA) stock?

DBV TECHNOLOGIES SA (DBV.PA) has a support level at 0.79 and a resistance level at 0.82. Check the full technical report for a detailed analysis of DBV.PA support and resistance levels.


Is DBV TECHNOLOGIES SA (DBV.PA) expected to grow?

The Revenue of DBV TECHNOLOGIES SA (DBV.PA) is expected to decline by -55.09% in the next year. Check the estimates tab for more information on the DBV.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy DBV TECHNOLOGIES SA (DBV.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does DBV TECHNOLOGIES SA (DBV.PA) stock pay dividends?

DBV.PA does not pay a dividend.


When does DBV TECHNOLOGIES SA (DBV.PA) report earnings?

DBV TECHNOLOGIES SA (DBV.PA) will report earnings on 2025-07-28.


What is the Price/Earnings (PE) ratio of DBV TECHNOLOGIES SA (DBV.PA)?

DBV TECHNOLOGIES SA (DBV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).


DBV.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to DBV.PA. When comparing the yearly performance of all stocks, DBV.PA is a bad performer in the overall market: 90.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DBV.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA. While DBV.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DBV.PA Financial Highlights

Over the last trailing twelve months DBV.PA reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 19.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.7%
ROE -91.83%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%-30.69%
Sales Q2Q%-49.52%
EPS 1Y (TTM)19.64%
Revenue 1Y (TTM)224.69%

DBV.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to DBV.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBV.PA


Ownership
Inst Owners29.72%
Ins Owners0.14%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.86
Price Target6.38 (685.71%)
EPS Next Y-36.93%
Revenue Next Year-55.09%